Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension by Laxminarayan G Hegde et al.
POSTER PRESENTATION Open Access
Comparative efficacy of AHU-377, a potent
neprilysin inhibitor, in two rat models of volume-
dependent hypertension
Laxminarayan G Hegde1*, Cecile Yu1, Cheruvu Madhavi1, Russell Araki1, Jennifer Villarreal1, Glenmar Obedencio3,
Anne Kanta3, Erik Sandvick2, Craig Hill2, Kevin Dement3, Uwe Klein2, Donavon McConn3, William Martin1,
Sharath S Hegde1
From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Halle, Germany. 24-26 June 2011
Background
Progressive hypertension and deteriorating renal func-
tion are hallmarks of cardio-renal syndromes. Histori-
cally, the deoxycorticosterone acetate (DOCA)-salt
model has been used to assess the therapeutic poten-
tial of antihypertensives in the setting of low renin and
volume-dependent hypertension. Dahl-salt-sensitive
(Dahl-SS) rats represent a genetic model of volume-
dependent hypertension and possess similar features to
the DOCA model, including higher natriuretic peptide
tone. Neprilysin inhibitors (NEPi) prevent the degrada-
tion of natriuretic peptides and activate cGMP signal-
ling pathways that regulate volume and blood pressure.
Antihypertensive effects of NEPi have been demon-
strated in both DOCA and Dahl-SS models; however,
the relative efficacy of NEPi in these two models has
not been studied directly. Here, we characterized the
natriuretic peptide tone in DOCA and Dahl-SS rats
and compared antihypertensive effects of a NEPi,
(AHU-377).
Methods
We determined the relationship between atrial natriure-
tic peptide (ANP) and blood pressure in anesthetized,
normotensive rats. We studied the relationship between
NEP inhibition and elevation of plasma cGMP evoked
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Figure 1 Comparison of peak fall in MAP (relative to baseline; A) and 12 hour vehicle adjusted AUC MAP (B) following oral administration of
AHU-377 (30 and100 mg/kg, PO) in conscious Dahl-SS and DOCA-salt hypertensive rats (n=4-7 per treatment group).
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by ANP in the absence and presence of AHU-377, an
ester prodrug of LBQ657 and a component of LCZ696
[1,2]. Finally, using telemetry, we assessed the antihyper-
tensive effects of AHU-377 in conscious Dahl-SS and
DOCA-salt models of hypertension.
Results
ANP reduced mean arterial pressure (MAP) by 4, 17, 29
and 34 mmHg at doses of 0.1, 1, 10 and 100 µg/kg IV,
respectively. ANP also promoted diuresis and increased
plasma and urinary cGMP. In normotensive rats, pre-
treatment with AHU-377 (3, 10 and 30 mg/kg, PO.)
augmented ANP-evoked plasma cGMP levels by 2.4, 3.3
and 4.0 fold, respectively (4h AUC compared to vehicle).
In Dahl-SS rats, AHU-377 (30 and 100 mg/kg, PO) pro-
duced a dose-dependent antihypertensive effect (Figure
1). By contrast, AHU-377 exerted only a modest reduc-
tion in MAP in the DOCA-salt hypertensive rats, despite
achieving estimated neprilysin enzyme occupancy of
>95% at highest dose tested (100 mg/kg, PO).
Conclusion
These studies confirm the role of the natriuretic peptide
system in blood pressure control. AHU-377 enhances
the tone of the natriuretic peptide system and exerts sig-
nificant antihypertensive effects. These effects were
more pronounced in Dahl-SS than in DOCA-salt rats.
The apparent higher sensitivity of Dahl-SS rats to nepri-
lysin inhibition suggest that this model could provide a
better method for testing the antihypertensive efficacy of
neprilysin inhibitors.
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